

Counsel, Boston

Life Sciences and Health Care



---

T: 617.573.4852  
F: 617.305.4852  
alexandra.gorman@skadden.com

---

## Education

J.D., Boston University School of Law, 2005 (Managing Editor, *Public Interest Law Journal*)

B.A. (Political Science), University of Pennsylvania, 2000

## Bar Admissions

Massachusetts

Alexandra Gorman represents pharmaceutical, medical device and biotech companies, and health care providers in connection with civil and criminal investigations, as well as in litigation, enforcement and regulatory matters.

Ms. Gorman has represented numerous pharmaceutical and medical device manufacturers, health maintenance organizations and corporations in False Claims Act and criminal or civil investigations and litigation by the U.S. Department of Justice. She has significant experience conducting internal investigations relating to the federal and state anti-kickback statutes, off-label promotion, Stark law, Medicare and Medicaid reimbursement, and other allegations of health care fraud and abuse. Ms. Gorman has counseled health care companies and individuals in connection with the Foreign Corrupt Practices Act, Food and Drug Administration, Office of Inspector General and other agency regulations. Ms. Gorman regularly advises clients on regulatory compliance matters, including voluntary disclosure of potential statutory and regulatory violations to appropriate government agencies and compliance with federal regulations regarding sales, marketing and pricing practices, medical affairs and clinical research. She also has managed discovery, settlement and pre-trial proceedings on behalf of pharmaceutical clients in products liability actions in Massachusetts.

Ms. Gorman is actively involved in the Boston Bar Association. She is a trustee of the Boston Bar Foundation, a member of the Boston Bar Foundation's Society of Fellows and has co-chaired the foundation's charitable fundraising events.

Prior to attending law school, Ms. Gorman was a legal assistant in the litigation department of Skadden's Boston office.

## Publications

"Biden Administration's Expected Impact on Health Care and Life Sciences Enforcement," *Skadden's 2021 Insights*, January 26, 2021

"HHS-OIG Signals Increasing Skepticism of Speaker Programs, Identifies Practices That Raise Compliance Red Flags," *Skadden, Arps, Slate, Meagher & Flom LLP*, November 23, 2020

"Healthcare Enforcement & Litigation: United States," *Getting the Deal Through*, 2018

"Aegerion Settles Criminal and Civil Probe of Promotional Practices, REMS and HIPAA Compliance, and Patient Assistance Programs," *Skadden, Arps, Slate, Meagher & Flom LLP*, September 28, 2017

"8 Years of Health Care Enforcement: Doing Less With More," *Law360*, August 10, 2017

"Trends in Corporate Integrity Agreements Reflect New HHS OIG Guidance on Use of Exclusion Authority," *Skadden, Arps, Slate, Meagher & Flom LLP*, March 13, 2017

"FDA Publications Double Down on Agency's Ability to Prohibit Off-Label Communications, but Narrow Scope of Debate," *Skadden, Arps, Slate, Meagher & Flom LLP*, February 1, 2017